Our research intends to obtain extra-cellular proteinogram of cell lines representing different advancement stages of prostate cancer and to test whether screened differential expression proteins can be secreted and used as serum biomarkers for prostate cancer. By examining differential expression spots in two extra-cellular protein 2D-PAGE gels and mass spectrum, candidate molecules were obtained. The expressions of these candidate molecules in eight cell lines and response to androgen stimulus in LNCaP were analyzed by RT-PCR. By constructing eukaryotic expression vectors and western-blotting with anti tags antibodies, the candidate molecules were tested to understand whether they can be expressed in transfected 293T cell culture fluid. Two overexpressed molecules-triosephosphate isomerase 1 (TPI1) and syndecan bind-ing protein, syntenin (ST1)-in extra-cellular proteinogram of C4-2 were screened out; both of them are secretary proteins. On transcriptional level, both proteins were up-regulated with the malignancy of prostate cancer cell lines and ST1 was dose-dependently inhibited by androgen. Considering cellular level results, both TPI1 and ST1 have their potential as serum biomarkers for indicating the developmental stage of prostate cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3724/sp.j.1005.2010.00235 | DOI Listing |
JAMA Netw Open
January 2025
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
Importance: The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA plus AAP.
Objective: To investigate the association of ADT plus AAP, APA alone, or APA plus AAP with health-related quality of life (HRQOL) in patients with advanced CSPC in the LACOG0415 trial.
Design, Setting, And Participants: The LACOG0415 randomized clinical trial comprised 128 patients with advanced CSPC who were randomized (1:1:1) to 1 of 3 treatment arms from October 16, 2017, to April 23, 2019.
World J Urol
January 2025
Research & Analysis Services, University Hospital Basel, Steinengraben 36, Basel, 4051, Switzerland.
Background: Multidisciplinary teams (MDTs) are essential for cancer care but are resource-intensive. Decision-making processes within MDTs, while critical, contribute to increased healthcare costs due to the need for specialist time and coordination. The recent emergence of large language models (LLMs) offers the potential to improve the efficiency and accuracy of clinical decision-making processes, potentially reducing costs associated with traditional MDT models.
View Article and Find Full Text PDFJ Mol Histol
January 2025
Department of Structural and Functional Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
This study investigated tempol action on genes and miRNAs related to NFκB pathway in androgen dependent or independent cell lines and in TRAMP model in the early and late-stages of cancer progression. A bioinformatic search was conducted to select the miRNAs to be measured based on the genes of interest from NFκB pathway. The miR-let-7c-5p, miR-26a-5p and miR-155-5p and five target genes (BCL2, BCL2L1, RELA, TNF, PTGS2) were chosen for RT-PCR and gene enrichment analyses.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
January 2025
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany.
Purpose: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in taxan-naïve patients is under current investigation.
Methods: We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxan-naïve mCRPC patients after previous ARPI treatment.
Psychooncology
January 2025
Health in Social Science, University of Edinburgh, Edinburgh, UK.
Objective: There is an increasing amount of literature acknowledging the significance of addressing the psychosocial impact of prostate cancer (PCa) on couples' relationship functioning and well-being. However, research on developing and evaluating psychological interventions for individuals and couples coping with PCa remains limited. This systematic review aimed to critically evaluate and synthesise the effectiveness of psychological interventions in improving the relationship functioning of couples affected by PCa and to identify the moderating role of several methodological characteristics of intervention studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!